NIR-activatable prodrugs for treating peritoneally metastasized ovarian cancers

Youngjae You Ph.D.

Principal Investigator

Agency: NIGMS/NIH (R01)


Ovarian cancer remains one of the most deadly forms of cancer because it is typically diagnosed after it has advanced to a late stage: current treatments cause significant side effects and have limited long-term success. Our research takes advantage of a unique synergistic combination of photodynamic therapy and local chemotherapy, and focuses on developing multifunctional prodrugs that are more effective and safer than current treatments. This strategy will be applicable for treating a wide range of diseases including ovarian cancer.